3results about How to "Promotes significant proliferation" patented technology

This invention belongs to the field of aquaculture technology and discloses a method for preparing a compound metabiotic to improve the stress resistance of aquatic animals and its application in feed. The invention discloses a method for preparing a compound metabiotic that employs a spatiotemporal sequential fermentation strategy of "first propagation, then induction, and finally compensation": First, Bacillus subtilis aerobic fermentation degrades the substrate to produce specific signal peptides; then, Lactobacillus plantarum and Saccharomyces cerevisiae are introduced, utilizing the previous metabolites to induce Lactobacillus plantarum to efficiently synthesize antimicrobial peptides and organic acids, and combined with the metabolic compensation effect of Saccharomyces cerevisiae, significantly enhancing the functional component gradient of the metabiotic. The compound metabiotic prepared by this invention has high concentrations of organic acids, active enzyme systems, and high release rates of β-glucan, which can significantly improve the stress resistance and survival rate of aquatic animals such as shrimp under extreme environments such as low salinity, high ammonia nitrogen, and low oxygen, solving the industry pain point of probiotic activity loss during high-temperature feed pelleting.

This invention relates to the field of biomedical technology, specifically disclosing a STING agonist ST-71, its synthesis method, and its applications. ST-71 is obtained by modifying SR-717. The STING agonist ST-71 synthesized in this invention has the characteristics of good antiviral effect, low toxicity and side effects, and cost-effectiveness, and can also inhibit the proliferation of porcine pseudorabies virus.

This invention discloses the application of catalpol in the preparation of drugs for the prevention and treatment of schizophrenia and the alleviation of the glucose and lipid metabolism side effects of olanzapine. Using a schizophrenia model mouse model induced by the commonly used MK801, the therapeutic effect of catalpol on schizophrenia was investigated, and the therapeutic effect of catalpol on the glucose and lipid metabolism side effects of the commonly used drug olanzapine was investigated through long-term gavage administration. A systematic study of catalpol was conducted from pharmacodynamic, behavioral, and morphological perspectives. The results showed that catalpol effectively improved the behavioral characteristics of the schizophrenia model mice, alleviated negative symptoms and cognitive impairment; catalpol effectively improved olanzapine-induced obesity and lipid metabolism disorders. This provides a theoretical research basis for the development of catalpol into a drug for the treatment of schizophrenia.